Kronox Lab Sciences Amends SPA; Lifts Lock-in On Erstwhile Promoters' 9.95% Stake

Key numbers

Market Cap	₹694.92 CrSpecialty Chemicals
P/E Ratio	24.32Sector PE 34.89
Promoter Holding	64.26%As of Oct 2026
1-Year Return	20.79%3Yr High ₹228.88

Key highlights

• Amendment executed on October 22, 2026, modifies the original SPA between Indo Borax and the Sellers
• Deletion of Clause 9.5 removes the lock-in restriction on the Sellers' remaining 9.95% shareholding
• Deletion of Clause 9.6 terminates Indo Borax's Right of First Refusal over the Sellers' retained shares
• Indo Borax and Zenrock Chemicals became the official promoters of the company on September 29, 2026
• The transaction relates to the majority transfer of 2,38,44,000 equity shares representing 64.26% stake

Strategic Amendment to Shareholder Restrictions

Kronox Lab Sciences Limited has received notification regarding a significant amendment to the Share Purchase Agreement (SPA) dated August 20, 2026. The amendment, executed on October 22, 2026, involves the purchaser, Indo Borax & Chemicals Limited, and the erstwhile promoters, including Mr. Ketan Vinodchandra Ramani and others.

By deleting Clause 9.5 and Clause 9.6 in their entirety, the parties have effectively removed the lock-in period previously imposed on the sellers' retained 9.95% shareholding. Furthermore, the purchaser will no longer hold a right of first refusal (ROFR) over these shares, granting the former promoters greater liquidity and freedom regarding their remaining equity interest in the specialty chemicals firm.

Timeline of Promoter Transition and Control

• August 20, 2026: Original SPA signed for the sale of 64.26% controlling stake to Indo Borax for ₹246.12 crore
• September 5, 2026: Draft Letter of Offer issued for an open offer to acquire an additional 25.79% stake
• September 29, 2026: Indo Borax officially classified as the promoter with Zenrock Chemicals joining the promoter group
• October 22, 2026: Amendment agreement finalized to ease restrictions on the sellers' residual equity
• The sellers, holding an aggregate of 9.95% stake, have now ceased to be part of the promoter group

Financial Performance and Sector Outlook

For the quarter ended June 30, 2026, Kronox Lab Sciences reported an operating revenue of ₹28.39 crore, marking a 16.88% year-on-year increase. The company maintained a strong operating profit margin of 31.7%, though slightly lower than the 32.8% recorded in the same period the previous year. Net profit for the quarter stood at ₹7.3 crore, reflecting 16.31% growth compared to the corresponding quarter in 2025.

With a Price-to-Earnings (P/E) ratio of 24.32, the company trades at a significant variation compared to the industry P/E of 40.84, while maintaining a Piotroski Score of 5, indicating moderate financial health amidst the leadership transition.

Expansion and Future Manufacturing Capabilities

Parallel to the change in control, Kronox Lab Sciences is aggressively pursuing capacity expansion. On October 14, 2026, the board approved the acquisition of a 5,000 square metre chemical manufacturing facility in the Dahej SEZ from Axiom Chemicals Private Limited. This move aligns with management's stated objective to develop a phased chemical manufacturing pipeline with a target capacity of up to 18,000 MTPA.

The company's operating model currently focuses on approximately 185 specialty chemical products, relying on a mix of recurring catalogue sales and spot purchase orders rather than a fixed long-term order book, providing flexibility as it integrates into the Indo Borax group.

What to watch next

• Board meeting to consider unaudited financial results for Q2 FY27 scheduled for November 3, 2026
• Completion of the Dahej SEZ plant acquisition from Axiom Chemicals by November 14, 2026
• Updates on the phased rollout of the 18,000 MTPA manufacturing capacity pipeline

Kronox Lab Sciences · financial snapshot

Share price	₹187.29
Market capitalisation	₹694.92 Cr
Revenue (annual)	₹101.22 Cr
Net profit (annual)	₹27.66 Cr
Revenue (latest quarter)	₹28.39 Cr+8.65% vs previous quarter
Net profit (latest quarter)	₹7.30 Cr-8.74% vs previous quarter
P/E (TTM)	24.32×Sector 34.89×
Promoter holding	64.26%-9.95% QoQ
FII holding	0.1%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.